N‐Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.

British Journal of Clinical Pharmacology

Volumn 40, Issue 6, 1995, Pages 531-538

  Gill, HJ ^a   Tingle, MD ^a   Park, BK ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DAPSONE; DRUG METABOLITE; HYDROXYLAMINE; KETOCONAZOLE; SULFAPHENAZOLE;

ARTICLE; BIOTRANSFORMATION; BLOOD TOXICITY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; HUMANS; HYDROXYLATION; KETOCONAZOLE; MIXED FUNCTION OXYGENASES; SULFAPHENAZOLE;

EID: 0029416939     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1995.tb05797.x     Document Type: Article

References (45)

1. Human liver microsomal N‐hydroxylation of dapsone by cytochrome P‐4503A4
2. Patient treatment compliance in leprosy—A critical review
3. AIDS‐related Pneumocystis carinii pneumonia successfully treated with dapsone and trimethoprim
4. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim‐sulphamethoxazole intolerant, HIV‐infected individuals
5. Drug hypersensitivity reactions and human immunodeficiency virus disease
6. Adverse reactions to trimethoprim‐sulfamethoxazole in patients with the acquired immunodeficiency syndrome
7. Adverse reactions to trimethoprim‐sulfamethoxazole in hospitalised patients
8. Bioactivation of dapsone to cytotoxic metabolite by human hepatic microsomal enzymes
9. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells
10. Studies on dapsone induced haemolytic anaemia: methaemoglobin production and glucose‐6‐phosphate activity in correlation with dapsone dosage
11. Role of DDS NOH in DD Sinduced haemolytic anaemia
12. Adverse drug reactions in HIV‐seropositive patients
13. Agranulocytosis associated with malarial prophylaxis with maloprim
14. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus‐infected patients
15. Adverse reactions to dapsone in persons infected with human immunodeficiency virus
16. Mechanisms of methaemoglobin formation by diphenyl sulfones. Effect of 4‐amino‐4′ hydroxy‐aminodiphenyl sulfone and other p‐substituted derivatives
17. Multiple regression analysis of antimalarial activities of sulphones and sulphonamides in cell‐free systems and principal component analysis to compare with antibacterial activities
18. The use of cimetidine as a selective inhibitor of dapsone N‐hydroxylation in man
19. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy
20. Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes
21. Protein measurement with the folin phenol reagent
22. The carbon monoxide binding pigment of liver microsomes
23. An investigation of the interaction between hal of antrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems
24. Studies of the metabolism of dapsone in man and experimental animals: Formation ofN‐hydroxy metabolites
25. Systemic glutathione deficiency in symptom‐free HIV‐sero‐positive individuals
26. Glutathione depletion in HIV infected patients: Role of cysteine deficiency and effect of oral N‐acetyl cysteine
27. Absence of correlation among three putative in vivo probes ofhuman cytochrome P4503A activity in young healthy men
28. Selective inhibitors of cytochrome P450
29. Cytochrome P450 inhibitors: Evaluation of specifies in the in vitro metabolism of therapeutics by human liver microsomes
30. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
31. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture
32. Pharmacogenetic phenotyping and genotyping
33. Human cytochromes P450; Problems and prospects
34. Polymerase chain reaction‐directed identification, cloning, and quantification of human CYP2C18 mRNA
35. Cytochrome P‐450‐dependent formation of reactive oxygen radicals: isozyme‐specific inhibition of P‐450‐mediated reduction of oxygen and carbon tetrachloride
36. Metabolism of dapsone in human liver by cytochrome P‐4502E1
37. Evaluation of triacetyloleandomycin, alpha‐naphth of lavone and diethyldithiocarbamate as selective chemical probes for inhibition of cytochromes P450
38. Clinicalpharmacokinetics ofcimetidine
39. The effect of preincubation with cimetidine on the N‐hydroxylation of dapsone by human liver microsomes
40. Differential inhibition of individual human liver cytochrome P‐450 by cimetidine
41. Selective inhibition of drug oxidation after simultaneous administration oftwoprobedrugs, antipyrineand tolbutamide
42. Cytochrome P4503A and the dapsone recovery ratio: Lack of inhibition by ketoconazole
43. Drug‐protein conjugation and its immunological consequences